STOCK TITAN

Abbott Laboratories (ABT) Financials

ABT NYSE
Trailing 12 months to September 30, 2026
Revenue $48.2B +10.0% YoY
Net Income $4.7B -66.4% YoY
EPS (Diluted) $2.69 -66.2% YoY
Free Cash Flow $6.8B -2.3% YoY
Market Cap $181.0B as of Nov 18, 2026
Price / Sales 3.8x on $48.2B revenue, trailing 12 months to September 30, 2026
Price / Earnings 38.5x on $4.7B net income, trailing 12 months to September 30, 2026
Price / Book 3.5x on $51.0B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ABT SEC filings page.

Abbott Laboratories (ABT) reported $48.2B in revenue over the twelve months to Sep 30, 2026, up 10.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ABT FY2025

Abbott’s 2025 results show a cash-generating business with improving margins, falling debt, and earnings distorted by a prior tax benefit.

FY2024 net income reached $13.4B alongside a $6.4B tax benefit, so that year’s profit is not a clean baseline. In FY2025, operating cash flow of $9.6B exceeded net income of $6.5B, indicating reported profit translated into cash rather than depending on the prior year’s tax-driven uplift.

Operating margin reached 18.2% in FY2025 after a 2.0 percentage-point improvement from FY2023, indicating operating costs absorbed growth more efficiently. Gross margin also improved to 56.4%, so the recovery was not limited to overhead control.

Debt-to-equity was 0.2x in FY2025 after long-term debt declined 21.6% from FY2024, indicating expansion was financed with less borrowing. Meanwhile, free cash flow of $7.4B exceeded capital spending of $2.2B, showing reinvestment did not absorb the cash generated by operations.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 68 / 100
Financial Health Score 68/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Abbott Laboratories's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
83

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Abbott Laboratories scores 83/100 on it among other operating companies.

Growth
49

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Abbott Laboratories scores 49/100 on it among other operating companies.

Leverage
75

Abbott Laboratories's net debt of $1.4B, being $9.9B of long-term debt less $8.5B of cash, came to 0.12 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Abbott Laboratories scores 75/100 among other operating companies measured the same way.

Liquidity
45

Abbott Laboratories held $1.58 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.58. Liquidity ranks operating companies on that ratio, and Abbott Laboratories scores 45/100 among other operating companies.

Cash Flow
79

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Abbott Laboratories scores 79/100 on it among other operating companies.

Returns
76

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Abbott Laboratories scores 76/100 on it among other operating companies.

Altman Z-Score Safe
4.89

Abbott Laboratories scores 4.89, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $181.0B against total liabilities of $34.6B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
5/9

Abbott Laboratories passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Cash-Backed
1.47x

For every $1 of reported earnings, Abbott Laboratories generates $1.47 in operating cash flow ($9.6B OCF vs $6.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
16.33x

Abbott Laboratories earns $16.33 in operating income for every $1 of interest expense ($8.1B vs $493.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$13.0B
YoY+14.5%
QoQ+3.3%
5Y CAGR+3.6%
10Y CAGR+9.4%

Abbott Laboratories generated $13.0B in revenue in Q3 2026. This represents an increase of 14.5% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.

EBITDA
$2.6B
YoY-8.2%
QoQ-5.0%
5Y CAGR-5.1%

Abbott Laboratories's EBITDA was $2.6B in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.2% from the same quarter a year earlier. Against the prior quarter it is down 5.0%.

Net Income
$920.0M
YoY-44.0%
QoQ-0.9%
5Y CAGR-15.2%
10Y CAGRn/m

Abbott Laboratories reported $920.0M in net income in Q3 2026. This represents a decrease of 44.0% from the same quarter a year earlier. Against the prior quarter it is down 0.9%.

EPS (Diluted)
$0.53
YoY-43.6%
QoQ0.0%
5Y CAGR-14.6%
10Y CAGRn/m

Abbott Laboratories earned $0.53 per diluted share (EPS) in Q3 2026. This represents a decrease of 43.6% from the same quarter a year earlier. It is unchanged from the prior quarter.

Cash & Balance Sheet

Free Cash Flow
$1.2B
YoY-46.6%
QoQ-38.5%
5Y CAGR-11.4%
10Y CAGR+3.1%

Abbott Laboratories generated $1.2B in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 46.6% from the same quarter a year earlier. Against the prior quarter it is down 38.5%.

Cash & Debt
$4.1B
YoY-46.1%
QoQ-20.6%
5Y CAGR-15.3%
10Y CAGR+4.9%

Abbott Laboratories held $4.1B in cash against $29.5B in long-term debt as of Q3 2026.

Dividends Per Share
$0.63
YoY+6.8%
QoQ0.0%

Abbott Laboratories paid $0.63 per share in dividends in Q3 2026. This represents an increase of 6.8% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding
1.73B
YoY-0.4%
QoQ+0.1%
5Y CAGR-0.4%
10Y CAGR+1.6%

Abbott Laboratories had 1.73B shares outstanding in Q3 2026. This represents a decrease of 0.4% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Margins & Returns

Gross Margin
56.8%
YoY+1.4pp
QoQ-1.0pp
5Y change-2.8pp
10Y change+2.5pp

Abbott Laboratories's gross margin was 56.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.

Operating Margin
10.4%
YoY-7.6pp
QoQ-3.0pp
5Y change-12.9pp

Abbott Laboratories's operating margin was 10.4% in Q3 2026, reflecting core business profitability. This is down 7.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.0 percentage points.

Net Margin
7.1%
YoY-7.4pp
QoQ-0.3pp
5Y change-12.2pp
10Y change+13.3pp

Abbott Laboratories's net profit margin was 7.1% in Q3 2026, showing the share of revenue converted to profit. This is down 7.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.

Return on Equity
1.8%
YoY-1.4pp
QoQ0.0pp
5Y change-4.3pp
10Y change+3.4pp

Abbott Laboratories's quarterly ROE was 1.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.4 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Capital Allocation

R&D Spending
$920.0M
YoY+20.1%
QoQ+3.1%
5Y CAGR+6.5%

Abbott Laboratories invested $920.0M in research and development in Q3 2026. This represents an increase of 20.1% from the same quarter a year earlier. Against the prior quarter it is up 3.1%.

Share Buybacks
$11.0M
YoY-96.4%
QoQ-98.9%
5Y CAGR-54.7%
10Y CAGR+18.6%

Abbott Laboratories spent $11.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 96.4% from the same quarter a year earlier. Against the prior quarter it is down 98.9%.

Capital Expenditures
$513.0M
YoY+3.4%
QoQ+3.2%
5Y CAGR+2.2%
10Y CAGR+5.1%

Abbott Laboratories invested $513.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 3.4% from the same quarter a year earlier. Against the prior quarter it is up 3.2%.

ABT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$13.0B+14.5%$12.6B+13.0%$11.2B+7.8%$11.5B+4.4%$11.4B+6.9%$11.1B+7.4%$10.4B+4.0%$11.0B+7.2%
Cost of Revenue$5.6B+10.9%$5.3B+9.7%$4.9B+9.4%$4.9B-0.4%$5.1B+8.0%$4.9B+5.5%$4.5B+0.1%$4.9B+8.5%
Gross Profit$7.4B+17.3%$7.3B+15.6%$6.3B+6.5%$6.5B+8.4%$6.3B+6.0%$6.3B+8.9%$5.9B+7.1%$6.0B+6.1%
R&D Expenses$920.0M+20.1%$892.0M+23.0%$767.0M+7.1%$735.0M-1.9%$766.0M+7.4%$725.0M+3.9%$716.0M+4.7%$749.0M+7.0%
SG&A Expenses$4.3B+39.8%$4.0B+30.2%$3.7B+22.2%$3.1B+7.6%$3.1B+5.4%$3.1B+5.3%$3.1B+3.4%$2.9B+6.7%
Operating Income$1.4B-34.0%$1.7B-17.5%$1.3B-20.6%$2.3B+17.8%$2.1B+10.7%$2.1B+22.9%$1.7B+22.2%$1.9B+7.4%
EBITDA$2.6B-8.2%$2.8B-2.7%$2.1B-12.3%$3.0B+12.0%$2.8B+7.1%$2.8B+14.3%$2.4B+11.8%$2.7B+4.8%
Interest Expense$350.0M+189.3%$351.0M+190.1%$174.0M+32.8%$120.0M-11.8%$121.0M-14.8%$121.0M-13.6%$131.0M-7.1%$136.0M-14.5%
Income Tax$311.0M-42.0%$596.0M+60.6%$372.0M-17.9%$582.0Mn/m$536.0M+82.3%$371.0M+21.6%$453.0M+114.7%-$7.2B-3681.6%
Net Income$920.0M-44.0%$928.0M-47.8%$1.1B-18.7%$1.8B-80.8%$1.6B-0.1%$1.8B+36.6%$1.3B+8.2%$9.2B+479.0%
EPS (Basic)$0.53-43.6%$0.53-48.0%$0.62-18.4%$1.01-80.9%$0.940.0%$1.02+37.8%$0.76+8.6%$5.28+473.9%
EPS (Diluted)$0.53-43.6%$0.53-47.5%$0.61-19.7%$1.02-80.6%$0.940.0%$1.01+36.5%$0.76+8.6%$5.26+478.0%
Diluted Shares (Avg)1.74B-0.7%1.74B-0.4%1.75B0.0%N/A1.75B+0.1%1.75B0.0%1.75B-0.1%N/A

ABT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$108.2B+28.6%$109.2B+30.0%$110.4B+35.6%$86.7B+6.5%$84.2B+13.2%$84.0B+15.0%$81.4B+12.4%$81.4B+11.2%
Current Assets$23.5B-5.4%$24.5B+0.2%$25.5B+10.2%$26.0B+9.9%$24.8B+4.4%$24.5B+5.8%$23.2B+3.5%$23.7B+4.3%
Cash & Equivalents$4.1B-46.1%$5.1B-26.6%$6.8B+4.1%$8.5B+11.9%$7.5B-0.6%$7.0B-0.5%$6.5B+3.9%$7.6B+10.4%
Short-Term Investments$246.0M+10.8%$499.0M+50.8%$492.0M+57.7%$417.0M+18.8%$222.0M-3.5%$331.0M+42.7%$312.0M-15.0%$351.0M-8.4%
Inventory$7.3B+9.4%$7.3B+5.2%$7.0B+5.3%$6.5B+4.7%$6.7B-1.5%$7.0B+2.1%$6.6B-2.8%$6.2B-5.7%
Accounts Receivable$9.0B+11.0%$8.6B+7.9%$8.2B+12.1%$7.9B+14.5%$8.1B+15.4%$8.0B+16.3%$7.3B+10.9%$6.9B+5.5%
Long-Term Investments$1.1B+15.6%$1.1B+16.0%$1.1B+20.2%$918.0M+3.6%$951.0M+4.3%$958.0M+9.2%$907.0M+10.9%$886.0M+10.9%
Goodwill$32.6B+36.2%$35.2B+47.1%$35.2B+50.8%$24.0B+4.0%$24.0B+1.3%$24.0B+2.8%$23.4B-0.1%$23.1B-2.4%
Total Liabilities$57.2B+72.2%$58.1B+73.8%$58.4B+78.8%$34.6B+2.5%$33.2B-3.9%$33.4B-0.8%$32.6B-3.0%$33.8B-2.5%
Current Liabilities$16.2B+10.8%$17.8B+32.6%$18.4B+41.3%$16.5B+16.5%$14.6B-2.1%$13.4B-2.3%$13.0B-7.3%$14.2B+2.3%
Non-Current Liabilities$41.1B+120.3%$40.3B+101.5%$40.0B+103.7%$18.1B-7.7%$18.6B-5.2%$20.0B+0.3%$19.6B0.0%$19.6B-5.7%
Long-Term Debt$29.5B+154.0%$29.6B+128.9%$29.6B+132.7%$9.9B-21.6%$11.6B-9.6%$12.9B-1.6%$12.7B+1.3%$12.6B-7.2%
Total Equity$51.0B+0.1%$51.1B+1.1%$52.1B+6.7%$52.1B+9.4%$51.0B+28.0%$50.6B+28.6%$48.8B+25.8%$47.7B+23.5%
Retained Earnings$49.6B+1.1%$49.8B+2.7%$50.0B+4.7%$49.8B+5.3%$49.1B+25.7%$48.5B+26.4%$47.7B+25.5%$47.3B+25.8%

ABT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$1.7B-37.7%$2.5B+21.5%$1.3B-7.2%$3.3B+15.6%$2.8B+3.0%$2.0B+4.4%$1.4B+38.2%$2.9B-5.6%
Depreciation & Amortization$1.3B+58.8%$1.1B+36.4%$803.0M+6.2%$792.0M-1.9%$791.0M-1.2%$777.0M-3.5%$756.0M-6.1%$807.0M-0.7%
Stock-Based CompensationN/AN/A$317.0M+9.7%N/AN/AN/A$289.0M-4.9%N/A
Capital Expenditures$513.0M+3.4%$497.0M-1.0%$399.0M-17.6%$689.0M-4.3%$496.0M-10.8%$502.0M-5.8%$484.0M+21.6%$720.0M-4.6%
Free Cash Flow$1.2B-46.6%$2.0B+28.9%$916.0M-1.8%$2.6B+22.3%$2.3B+6.6%$1.5B+8.3%$933.0M+48.8%$2.1B-5.9%
Investing Cash Flow-$385.0Mn/m-$673.0Mn/m-$20.3Bn/m-$913.0Mn/m-$457.0Mn/m-$582.0Mn/m-$470.0Mn/m-$866.0Mn/m
Financing Cash Flow-$2.4Bn/m-$3.5Bn/m$17.3Bn/m-$1.4Bn/m-$1.8Bn/m-$1.1Bn/m-$2.1Bn/m-$1.9Bn/m
Dividends Paid$1.1B+6.1%$1.1B+7.1%$1.1B+7.0%$1.0B+7.5%$1.0B+7.4%$1.0B+7.1%$1.0B+7.2%$958.0M+7.9%
Share Buybacks$11.0M-96.4%$1.0B+17316.7%$180.0M-35.7%$302.0M-4.1%$305.0M-59.4%$6.0M+100.0%$280.0M+23.9%$315.0M+21.6%

ABT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin56.8%+1.4pp57.7%+1.3pp56.2%-0.7pp57.0%+2.1pp55.4%-0.5pp56.4%+0.8pp56.9%+1.6pp55.0%-0.5pp
Operating Margin10.4%-7.6pp13.4%-5.0pp12.0%-4.3pp19.6%+2.2pp18.1%+0.6pp18.4%+2.3pp16.3%+2.4pp17.4%0.0pp
Net Margin7.1%-7.4pp7.4%-8.6pp9.7%-3.1pp15.5%-68.6pp14.5%-1.0pp16.0%+3.4pp12.8%+0.5pp84.1%+68.5pp
Return on Equity1.8%-1.4pp1.8%-1.7pp2.1%-0.6pp3.4%-16.0pp3.2%-0.9pp3.5%+0.2pp2.7%-0.5pp19.4%+15.2pp
Return on Assets0.9%-1.1pp0.9%-1.3pp1.0%-0.6pp2.1%-9.3pp1.9%-0.3pp2.1%+0.3pp1.6%-0.1pp11.3%+9.2pp
Current Ratio1.45-0.2x1.38-0.4x1.39-0.4x1.58-0.1x1.70+0.1x1.82+0.1x1.78+0.2x1.670.0x
Debt-to-Equity0.58+0.3x0.58+0.3x0.57+0.3x0.19-0.1x0.23-0.1x0.26-0.1x0.26-0.1x0.26-0.1x
Liabilities-to-Equity1.12+0.5x1.14+0.5x1.12+0.5x0.660.0x0.65-0.2x0.66-0.2x0.67-0.2x0.71-0.2x
Asset Turnover0.120.0x0.120.0x0.100.0x0.130.0x0.140.0x0.130.0x0.130.0x0.130.0x
FCF Margin9.4%-10.7pp15.8%+1.9pp8.2%-0.8pp22.9%+3.3pp20.2%-0.1pp13.9%+0.1pp9.0%+2.7pp19.6%-2.7pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Abbott Laboratories ABT FY2025 $44.3B $6.5B 14.7% $181.0B 68/100
Medtronic plc MDT FY2026 $36.4B $4.8B 13.2% $128.8B 63/100
Stryker Corporation SYK FY2025 $25.1B $3.2B 12.9% $121.1B 69/100
Boston Scientific Corporation BSX FY2025 $20.1B $2.9B 14.4% $63.3B 66/100
Edwards Lifesciences Corp EW FY2025 $6.1B $1.1B 17.7% $60.5B 72/100
DexCom, Inc. DXCM FY2025 $4.7B $836.3M 17.9% $30.8B 74/100

Frequently Asked Questions

Abbott Laboratories (ABT) reported $44.3B in total revenue for fiscal year 2025. This represents a 5.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Abbott Laboratories (ABT) revenue grew by 5.7% year-over-year, from $42.0B to $44.3B in fiscal year 2025.

Yes, Abbott Laboratories (ABT) reported a net income of $4.7B over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $6.5B, with a net profit margin of 14.7%.

Abbott Laboratories (ABT) reported diluted earnings per share of $3.72 for fiscal year 2025. This represents a -51.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Abbott Laboratories (ABT) had EBITDA of $11.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Abbott Laboratories (ABT) had $8.5B in cash and equivalents against $9.9B in long-term debt.

Abbott Laboratories (ABT) had a gross margin of 56.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Abbott Laboratories (ABT) had an operating margin of 18.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Abbott Laboratories (ABT) had a net profit margin of 14.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Abbott Laboratories (ABT) paid $2.40 per share in dividends during fiscal year 2025.

Abbott Laboratories (ABT) has a return on equity of 12.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Abbott Laboratories (ABT) generated $7.4B in free cash flow during fiscal year 2025. This represents a 16.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Abbott Laboratories (ABT) generated $9.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Abbott Laboratories (ABT) had $86.7B in total assets as of fiscal year 2025, including both current and long-term assets.

Abbott Laboratories (ABT) invested $2.2B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Abbott Laboratories (ABT) invested $2.9B in research and development during fiscal year 2025.

Yes, Abbott Laboratories (ABT) spent $893.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Abbott Laboratories (ABT) had 1.74B shares outstanding as of fiscal year 2025.

Abbott Laboratories (ABT) had a current ratio of 1.58 as of fiscal year 2025, which is generally considered healthy.

Abbott Laboratories (ABT) had a debt-to-equity ratio of 0.19 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Abbott Laboratories (ABT) had a liabilities-to-equity ratio of 0.66 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Abbott Laboratories (ABT) had a return on assets of 7.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Abbott Laboratories (ABT) trades at 38.5x earnings, its market capitalization divided by $4.7B net income, trailing 12 months to September 30, 2026. The market capitalization is $181.0B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Abbott Laboratories (ABT) trades at 3.8x sales, its market capitalization divided by $48.2B revenue, trailing 12 months to September 30, 2026. The market capitalization is $181.0B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Abbott Laboratories (ABT) has an Altman Z-Score of 4.89, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Abbott Laboratories (ABT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Abbott Laboratories (ABT) has an earnings quality ratio of 1.47x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Abbott Laboratories (ABT) has an interest coverage ratio of 16.33x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Abbott Laboratories (ABT) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top